2017
DOI: 10.33140/ijcrt/02/02/00006
|View full text |Cite
|
Sign up to set email alerts
|

The Rediscovery of Bisantrene: A Review of the Literature

Abstract: Bisantrene is an anthracene with anthracycline-like antitumor activity that has been the subject of over 60 clinical trials but which was lost for over 30 years due to various merger and acquisition transactions. In over 2000 patients, bisantrene has been well tolerated and shown to lack the cardiac dose-limiting toxicity of the anthracycline class and perhaps to lack a propensity to induce multi-drug resistance. Aside from inhibition of topoisomerase II, macrophage-activating activity and telomerase inhibitin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 45 publications
(65 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?